Latest Insider Transactions at Ani Pharmaceuticals Inc (ANIP)
This section provides a real-time view of insider transactions for Ani Pharmaceuticals Inc (ANIP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ANI PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ANI PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2023
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Direct |
13,500
-64.57%
|
$688,500
$51.38 P/Share
|
|
Jun 21
2023
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Direct |
11,843
-36.16%
|
$603,993
$51.95 P/Share
|
|
Jun 20
2023
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Direct |
14,657
-30.92%
|
$747,507
$51.93 P/Share
|
|
May 23
2023
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,865
+15.78%
|
-
|
|
May 23
2023
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,865
+12.72%
|
-
|
|
May 23
2023
|
David Nash Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,865
+15.11%
|
-
|
|
May 23
2023
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,865
+15.94%
|
-
|
|
May 23
2023
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,865
+8.9%
|
-
|
|
May 23
2023
|
Renee P Tannenbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,865
+25.35%
|
-
|
|
Apr 10
2023
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,289
-1.71%
|
$86,982
$38.5 P/Share
|
|
Apr 10
2023
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,534
-2.55%
|
$172,292
$38.5 P/Share
|
|
Mar 28
2023
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,420
-1.02%
|
$53,960
$38.62 P/Share
|
|
Mar 28
2023
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-0.46%
|
$19,912
$38.62 P/Share
|
|
Mar 23
2023
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,224
-2.95%
|
$156,288
$37.82 P/Share
|
|
Mar 23
2023
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,455
-6.51%
|
$645,835
$37.82 P/Share
|
|
Mar 23
2023
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,452
-2.13%
|
$90,724
$37.82 P/Share
|
|
Mar 07
2023
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,662
-2.45%
|
$601,128
$44.23 P/Share
|
|
Mar 07
2023
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,503
-1.2%
|
$154,132
$44.23 P/Share
|
|
Mar 07
2023
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,342
-3.26%
|
$103,048
$44.23 P/Share
|
|
Mar 07
2023
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,902
-2.43%
|
$83,688
$44.23 P/Share
|
|
Mar 07
2023
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,460
-1.05%
|
$108,240
$44.23 P/Share
|
|
Feb 28
2023
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
40,526
+10.71%
|
-
|
|
Feb 28
2023
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
159,216
+17.53%
|
-
|
|
Feb 28
2023
|
James G. Marken SVP OPS & PROD DEV |
BUY
Grant, award, or other acquisition
|
Direct |
21,710
+7.76%
|
-
|
|
Feb 28
2023
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
28,947
+19.4%
|
-
|
|
Feb 28
2023
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Direct |
28,947
+26.14%
|
-
|
|
Feb 28
2023
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
20,262
+22.45%
|
-
|
|
Feb 28
2023
|
Krista Davis SVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,262
+23.96%
|
-
|
|
Feb 28
2023
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Grant, award, or other acquisition
|
Direct |
28,947
+39.29%
|
-
|
|
Feb 28
2023
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
28,947
+20.39%
|
-
|
|
Feb 15
2023
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,275
-3.39%
|
$57,375
$45.04 P/Share
|
|
Feb 15
2023
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,292
-3.16%
|
$58,140
$45.04 P/Share
|
|
Dec 01
2022
|
Meridian Venture Partners Ii LP > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
200,000
-9.01%
|
$7,600,000
$38.5 P/Share
|
|
Sep 12
2022
|
Krista Davis SVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
16,433
+50.0%
|
-
|
|
Sep 08
2022
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,646
-1.28%
|
$134,902
$37.61 P/Share
|
|
Aug 15
2022
|
James G. Marken SVP OPS & PROD DEV |
SELL
Open market or private sale
|
Direct |
5,172
-4.21%
|
$191,364
$37.79 P/Share
|
|
Aug 12
2022
|
James G. Marken SVP OPS & PROD DEV |
SELL
Open market or private sale
|
Direct |
12,894
-9.5%
|
$477,078
$37.04 P/Share
|
|
Jul 18
2022
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
19,280
+50.0%
|
-
|
|
Apr 27
2022
|
Robert E. Brown Jr |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+17.01%
|
-
|
|
Apr 27
2022
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+13.67%
|
-
|
|
Apr 27
2022
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+25.52%
|
-
|
|
Apr 27
2022
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+25.24%
|
-
|
|
Apr 27
2022
|
David Nash Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+24.07%
|
-
|
|
Apr 27
2022
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+19.98%
|
-
|
|
Apr 27
2022
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,352
+10.46%
|
-
|
|
Apr 27
2022
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
11,291
+7.15%
|
-
|
|
Apr 27
2022
|
James G. Marken SVP OPS & PROD DEV |
BUY
Grant, award, or other acquisition
|
Direct |
6,644
+4.67%
|
-
|
|
Apr 27
2022
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
6,476
+13.68%
|
-
|
|
Apr 27
2022
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
6,476
+14.68%
|
-
|
|
Apr 10
2022
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,534
-3.24%
|
$131,486
$29.91 P/Share
|